

New Evidence-Based Guideline on Molecular Biomarkers for Colorectal Cancer

A multidisciplinary perspective to optimize patient care.

The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) collaborated to develop a clinical practice guideline on molecular biomarker testing for patients with early and advanced colorectal cancer. This evidence-based clinical practice guideline will help establish standard molecular biomarker testing, guide targeted therapy decisions, and advance personalized care for these patients.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology

Twenty-one guideline statements were developed to ensure colorectal cancer patients receive the most effective targeted treatment for their type of cancer.



4,000+ articles
considered for review



More than 25 expert
specialists involved

Colorectal cancer is the second leading cause of cancer death in men and women in the U.S. combined.

Source: American Cancer Society 2017

Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Arch Pathol Lab Med.* 2017;141(5):625-657. doi: [10.5858/arpa.2016-0554-CP](https://doi.org/10.5858/arpa.2016-0554-CP)